Clinical Trial Update: Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 autologous memory-like NK cell therapy trial in multiple myeloma using BHV-1100 with low-dose IL-2, sponsored by B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BHV-1100
• Interleukin-2 (low-dose) (interleukin-2)

Snippet

Sponsor: Biohaven Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED